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1A MYRIAD OF REASONS: INCENTIVES FOR INNOVATION 
IN GENETIC RESEARCH AND DIAGNOSTICS POST-
MYRIAD
ZACHARY KLING* 
INTRODUCTION
Imagine a world in which the very essence of your being is owned 
by various corporations and institutions.  These groups profit off of 
ascertaining exactly what is contained within your genetic code. They 
exclude you and others from learning what your code says about you, 
unless you pay them for the information. In a manner, this is what 
has been happening in the field of genetic diagnostics for many years 
XQWLO WKH 6XSUHPH &RXUW¶V GHFLVLRQ LQ Association for Molecular   
Pathology v. Myriad.1
On January 3, 2000, British artist Donna Rawlinson Maclean       
attempted to reserve her unique genetic code by submitting a patent 
application titled ³0\VHOI´2 She filed her application, GB0000180.0, 
in the British Patent Office to protest the above-described scenario.3
Brian Caswell, an agent at the British Patent Office, seemed confused 
as to why someone would submit such a patent.4  On the topic of the 
SDWHQW DSSOLFDWLRQ &DVZHOO VDLG ³,W LV QRW UHDOO\ ZRUWK SDWHQWLQJ
VRPHWKLQJXQOHVV\RXPDNHDORWRIPRQH\IURPLW´5
                                                                                                                          
* J.D. Candidate at Indiana University Robert H. McKinney School of Law. 
1.See $VV¶QIRU0ROHFXODU3DWKRORJ\Y0\ULDG*HQHWLFV,QF6&W
(2013). 
2. Of Her Own Making, N. Y. TIMES, (Mar. 12, 2000),
http://www.nytimes.com/2000/03/12/business/business-diary-of-her-own-
making.html, archived at http://perma.cc/CQ6K-MXSV. 
3. Id. 
4.Woman Files Patent Application on Herself, INST. FOR AGRIC. AND TRADE 
32/¶<0DUKWWSLDWSRUJnews/biotech-activists-030300-woman-files-
patent-application-on-herself, archived at http://perma.cc/M5K9-XKSJ. 
5. Id.
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Undoubtedly, Ms. Maclean was not likely to realize robust profits 
from her patent, or any at all, but a lot of money had been made from 
products protected from competition by genetic patents at that time.  
For instance, in the year 2000, one product protected by a gene patent 
DFFRXQWHGIRUPRUHWKDQELOOLRQRIRQHFRPSDQ\¶VELOOLRQLQ
total revenue.6
The commercializatLRQ DQGPRQRSROL]DWLRQ RI KXPDQLW\¶V VKDUHG
genetic code disturbed more than just a British performance artist 
with a flair for the dramatic.  Other parties concerned with the       
patenting of human genes included medical professionals, researchers 
in genetic epidemiology, and policy-makers to name a few.7
As the years went on, more and more of the human genome        
became patented.8 In 2009, the controversy came to a head when the 
American Civil Liberties Union (ACLU) filed a lawsuit in the    
Southern District of New York naming twenty plaintiffs that included 
the United States Patent Office, Myriad Genetics, and ten directors of 
the University of Utah Research Foundation as defendants.9
This case went all the way to the Supreme Court.10  In the summer 
of 2012, in a decisive, unanimous decision penned by Justice    
Thomas, the Court found for the plaintiffs on patents that claimed 
genomic DNA.11  In this single decision, the Court invalidated the 
patents that laid the foundation for an entire industry.12
The decision was a hard-won victory for those concerned with the 
ability of private companies to own the rights to the human genetic 
                                                                                                                          
6.See Amy Tsao, Amgen: Will Bigger Be Better? BUSINESS WEEK ONLINE, Jan. 2, 
2002, 
http://www.businessweek.com/bwdaily/dnflash/jan2002/nf2002012_2995.htm.
(EpoGen, a product protected by a patent on the human erythropoietin gene,     
DFFRXQWHGIRUELOOLRQGROODUVRI$PJHQ¶VQHDUO\ELOOLRQGROODUUHYHQXHV
7.Lori B. Andrews, The Gene Patent Dilemma: Balancing Commercial Incentives 
with Health Needs, 2 HOUS. J. HEALTH L. & POL¶Y 65, 66 (2002). 
8.Kyle Jensen & Fiona Murray, Intellectual Property Landscape of the Human 
Genome, 310 SCIENCE (5746) 239-240 (October 14, 2005).
9.28 U.S.C. $VV¶QIRU0ROHFXODU3DWKRORJ\Y8QLWHG6WDWHV3DWHQWDQG
Trademark Office, 702 F. Supp. 2d 181 (S.D.N.Y. 2010). 
10.See generally $VV¶QIRU0ROHFXODU3DWKRORJ\Y0\ULDG*HQHWLFV,QF6&W
2107 (2013). 
11.Id. at 2119.
12. Id.
2016 A MYRIAD OF REASONS  3
code, but is it possible that they were shortsighted and focused too 
QDUURZO\ RQ WKH VHHPLQJO\ XQMXVW QDWXUH RI ³RZQLQJ´ D SHUVRQ¶V
genetic code?  After all, the genes in question in Myriad were being 
used to identify whether a person may develop breast cancer, a    
laudable goal.  Perhaps without the security of genetic patents,      
researchers would no longer be encouraged to find such gene-to-
disease correlations. Perhaps that may be the case, but is there      
anything left to incentivize researchers? And, if there is, what exactly 
is left to incentivize these innovative genetic diagnostics companies? 
This Note addresses the incentives remaining for innovation in the      
genetLF GLDJQRVWLFV ILHOG DIWHU WKH 6XSUHPH &RXUW¶V GHFLVLRQ LQ WKH
Myriad case.  Part I is an overview of patent law in the United States 
GHYHORSV WKH UHDGHU¶V XQGHUVWDQGLQJ RI ZKDW D patent is, what is   
generally patentable, and the steps necessary to secure a patent in the 
United States.  Part II discusses genes, genetic diagnostics, and gene 
patents.  Part III delves into the controversy surrounding gene       
patents, including a discussion of both SURSRQHQW¶V DQG RSSRQHQW¶V
positions on the granting of gene patents.   
Part IV contains a discussion of Myriad from the district court 
all the way up to the Supreme Court that lays out the legal rationale 
behind the invalidation of patents the genetic diagnostics community 
believed were invaluable to their field.  Finally, Part V analyzes what 
remains post-Myriad to incentivize genetic researchers to look for 
gene sequence associations to diseases and to develop the diagnostics 
to test for these gene sequences.  This final Part reveals that not all 
was lost due to the invalidation of key patents protecting the industry 
and that many means remain by which genetic researchers and      
diagnostics providers can maintain incentive and competitive        
advantage to continue their work. 
I. PATENT LAW IN THE UNITED STATES
Patent law in the United States has its foundation in the Constitu-
tion.13 7KH³,QWHOOHFWXDO3URSHUW\´FODXVHWKH´,3FODXVH´RU³SDWHQW
DQG FRS\ULJKW FODXVH´ FRQIHUV XSRQ the government of the United 
States the authority and obligation to provide protection to those who 
                                                                                                                          
13.See U.S. CONST. art. I, § 8, cl. 8. 
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advance the sciences or the useful arts.14  The IP clause can be found 
at Article 1, Section 8, Clause 8 of the United States Constitution and 
provides CongrHVV ZLWK WKH SRZHU ³>W@R SURPRWH WKH SURJUHVV RI
science and useful arts, by securing for limited time to authors and 
inventors the exclusive right to their respective writings and          
GLVFRYHULHV´15  Inventors who have patents issued to them are      
UHIHUUHGWRDV³SDWHQWHHV´16
To this end, Congress has enacted legislation to protect inventors 
DQG WKHLU DGYDQFHV WR WKH ³XVHIXO DUWV´ E\ SURYLGLQJ SURWHFWLRQ
through what is known as a patent.17  According to the United States 
Patent and Trademark OffLFHWKH³86372´WKHDJHQF\UHVSRQVLEOH
for the issuance of patents and trademark registrations within the 
United States, a patent is: 
a property right granted by the Government of the United 
6WDWHV RI $PHULFD WR DQ LQYHQWRU µWR H[FOXGH RWKHUV IURP
making, using, offering for sale, or selling the invention 
throughout the United States or importing the invention into 
WKH8QLWHG 6WDWHV¶ IRU D OLPLWHG WLPH LQ H[FKDQJH IRU SXEOLF
disclosure of the invention when the patent is granted.18
Thus, patent rights are a negative property right.19  Holding a patent 
alone does not allow a patentee to actually practice, make, or even 
use their invention.20  The patent, as explained in the above quoted 
language, allows only the power to exclude others from making use 
of the patented invention.21  A prime example of this is in the     
pharmaceutical industry. Almost every pharmaceutical product has, 
at least at the beginning of its lifecycle, various patents that claim the 
chemical composition of the drug or the formulation of the drug 
                                                                                                                          
14. Id.
15. Id.
16.35 U.S.C. § 100(d) (2015). 
17.See generally 35 U.S.C. §§ 101-103 (2015). 
18.Patents for Inventors, USPTO (Jan. 26, 2015),
http://www.uspto.gov/inventors/patents.jsp, archived at http://perma.cc/7YYP-
RKYP. 
19. Id. 
20. Id. 
21.Id.; see also 35 U.S.C. § 271 (concerning infringement of patents). 
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product made with that chemical composition.22  Yet, to reach the 
market and actually be able to sell their inventions, innovator     
pharmaceutical companies must jump through the regulatory hoops 
RIWKH)RRGDQG'UXJ$GPLQLVWUDWLRQWKH³)'$´23
Patents in the United States are more fully governed by the Patent 
Act, which is codified at 35 U.S.C. §§ 1±376. To be granted a patent, 
Congress established that the claimed invention must be patentable 
subject matter as defined in 35 U.S.C. § 101.  Patentable subject   
PDWWHU LV GHILQHG DV ³DQ\ QHZ DQG XVHIXO SURFHVV PDFKLQH        
manufacture, or composition of matter, or any new and useful       
LPSURYHPHQW WKHUHRI´24  This definition has been found to exclude 
from the realm of patentable subject matter inventions that claim 
laws of nature, products of nature, or abstract ideas.25
Further requirements for patentability include novelty,              
non-obviousness, and utility.26  Novelty generally requires that the 
claimed invention be one that is new and has not been claimed in a 
previous patent application in the United States or any other        
country.27  Non-obviousness requires that the invention or            
modification to a prior invention not be obvious to a person who has 
ordinary skill in the science underlying the invention.28 Utility      
requires that an invention have some use.29  Thus, one cannot patent 
something that has no use or purpose capable of being exploited.30
                                                                                                                          
22.Katherine N. Addison, The Impact of the Biosimilars Provision of the Heath 
Care Reform Bill on Innovation Investments, 10 J. MARSHALL REV. INTELL. PROP.
L. 553, 571 (2011). 
23.21 U.S.C. § 355(a); See also Katherine N. Addison, The Impact of the          
Biosimilars Provision of the Heath Care Reform Bill on Innovation Investments, 10 
J. MARSHALL REV. INTELL. PROP. L. 553, 571 (2011).
24.35 U.S.C. § 101 (2012). 
25.Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980). 
26.35 U.S.C. §§ 101-103 (2012). 
27.35 U.S.C. § 102 (2012). 
28.35 U.S.C. § 103 (2012). 
29.See 35 U.S.C. § 101 (2012). 
30. Id.
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II. GENES: WHAT ARE THEY AND HOW CAN YOU PATENT THEM? 
A. What is DNA? 
When the ordinary, non-scientist thinks of a gene, he or she most 
OLNHO\ XQGHUVWDQGV WKDW JHQHWLF LQIRUPDWLRQ LV FDUULHG LQ D SHUVRQ¶V
DNA, and their individual genes are somehow responsible for      
making them who they are.  It then follows from that understanding 
that a single gene is the section of DNA that provides for some    
physical characteristic or trait of an individual.31  At the most basic 
level, this is essentially correct.  However, a little more depth on the 
topic of precisely what a gene is and how they have been claimed in 
patents will help lay the groundwork for the discussion at hand. 
That simplistic take on what a gene is should generally be a        
satisfactory working definition for most people, but how do          
professional geneticists and other scientists define a gene?  Those 
scientists cannot even decide what exactly the definition of a gene 
ought to be.32  As scientists learn more about biology, and genetics 
specifically, the definition of what a gene is and exactly what it does 
are in flux.33
Deoxyribonucleic acid (DNA) is the source code for everything 
human bodies are programmed to do.34  This includes the information 
that is eventually responsible for eye color, hair color, the growth of 
limbs, and the ability of nerves to transmit sensations to the brain.35
DNA is structured in a twisted double helix, like a spiraling ladder.36
                                                                                                                          
31.Black Bag at BB4, OAK RIDGE NATIONAL LABORATORIES, available at 
http://www.ornl.gov/sci/techresources/Human_Genome/publicat/, archived at 
http://perma.cc/29E8-FGQ6 
32.See Andrew W. Torrance, Gene Concepts, Gene Talk, and Gene Patents, 11 
MINN. J.L. SCI. & TECH³>'@HEDWHVDERXWZKDWDµJHQH¶UHDOO\LV
have raged within the 
biology FRPPXQLW\´
33.Id. at 160-61. 
34.See generally National Institutes of Health, A Brief Guide to Genomics, 
NATIONAL                                                                                                         
HUMAN GENOME RESEARCH INSTITUTE, http://www.genome.gov/18016863,     
archived at http://perma.cc/H2GR-JAD7. 
35.OAK RIDGE NATIONAL LABORATORIES, supra note 31, at BB4 
36.James D. Watson & Francis H. C. Crick, A Structure for Deoxyribose Nucleic 
Acid, 171 NATURE 737 (1953) (unveiling the twisted-helix DNA structure that 
Watson and Crick discovered). 
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On each side of the ladder are strands of deoxyribose, which is a   
sugar, and some phosphate molecules.37  Connecting the sides of the 
ladder is a nucleotide pair, referred to as a base pair.38  Nucleotides 
consist of four different chemicals, each of which is referred to by a 
VLQJOH OHWWHU DGHQLQH ³$´ JXDQLQH ³*´ WK\PLGLQH ³7´ DQG
F\WRVLQH³&´39  In these base pairs, an A is always paired with a T, 
while a G is always paired with a C.40  Each strand of DNA, split 
down the middle of the ladder, can then be expressed as a sequence 
identified by letters corresponding to each nucleotide in the           
sequence.41  Found in this string of letters are  certain three-letter  
nucleotide sequences that code for the production of an amino acid, 
the basic building blocks of proteins.42  These sequences are called 
³FRGRQV´43  Codons work together to provide for the synthesis of 
proteins.44  These cooperaWLQJ FRGRQV DUH FDOOHG ³H[RQV´45
However, exons are only a tiny fraction of the human genome and 
are frequently not contiguous in the DNA sequence. 46, 47  It turns out 
that most of the human genome is not responsible for the               
programming of anything.48  These portions of DNA sequence that 
GR QRW FRGH IRU DPLQR DFLG SURGXFWLRQ DUH FDOOHG ³LQWURQV´ ZKLFK
comprise over ninety-eight percent of the human genome.49
Human gene patents are written to claim the isolated strand of 
DNA that contains a group of exons found to code for some trait that 
                                                                                                                          
37.See NATIONAL HUMAN GENOME RESEARCH INSTITUTE, supra note 34. 
38.Jonah D. Jackson, Note, SOMETHING LIKE THE SUN: WHY EVEN 
³,62/$7('$1'385,),('´*(1(6$5(352'8&762)1$785(, 89 
TEX..L. REV. 1453, 1458 (2011). 
39.NATIONAL HUMAN GENOME RESEARCH INSTITUTE, supra note 34. 
40.Jackson, SUPRA NOTE 38, at 1458. 
41. Id.
42. Id.
43. Id.
44. Id.
45. Id.
46.Anthony J. F. Griffiths et. al., MODERN GENETIC ANALYSIS  
INTEGRATING 
GENES AND GENOMES, at 302 (2d ed. 2002). 
47.Jackson, SUPRA NOTE 38, at 1458. 
48.OAK RIDGE NATIONAL LABORATORIES, supra note 31, at BB5. 
49.Id. ³/HVVWKDQRIWKHJHQRPHFRGHVIRUSURWHLQV´
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may be commercially valuable.50  These patents are filed as         
composition-of-matter patents claiming the actual, genomic DNA.51
The USPTO also granted patents claiming what is known as      
complementary DNA, or cDNA.52  Complementary DNA is a              
synthetically produced copy of DNA that contains only the active 
exons of a gene.53 7KHSURFHVVXVHGWRFUHDWHF'1$LV³ZHOONQRZQ
LQ WKH ILHOG RI JHQHWLFV´ DQG ³>R@QH VXFK PHWKRG EHJLQV ZLWK D
messenger RNA molecule, a naturally occurring ribonucleic strand 
that contains only exons, and uses [it] to create a new, synthetic DNA 
PROHFXOH´54
III. GENE PATENTS IN THE UNITED STATES
The history of gene patents in the United States starts in 1973.55  In 
that year, the USPTO issued the first patent that included DNA as an 
element of the claimed material.56  Later that same year, the USPTO 
issued a patent that claimed a gene as an element in the production of 
commercial hybrid maize.57  In 1982, the USPTO granted the first 
patent application directed to human and animal genes.58
The Supreme Court first addressed the validity of patents claiming 
the genetic material of living beings in Diamond v. Chakrabarty.59
In that case, the USPTO denied a patent application claiming a      
bacterium that was created through the combined DNA of four other 
microbes.60  The application was denied because, at the time of the 
application, it was thought that claims to living things were not pa-
                                                                                                                          
50.See generally Jackson, supra note 38 (discussing the isolation and purification 
doctrine as it relates to the patenting of genes as compositions of matter). 
51.Id. at 1453. 
52.See generally Myriad Genetics, Inc., 133 S.Ct. 2107. 
53.Id. at 2112. 
54. Id.
55.Torrance, supra note 32, at 176.
56. Id.
57. Id.
58.Id. at 176-77 FODLPLQJD³>U@HFRPELQDQW DNA vector[s] comprising specified 
QXFOHRWLGHVHTXHQFHVRIFRGRQVIRUµKXPDQFKRULRQLFVRPDWRPDPPRWURSLQ¶DQG
µWKHJURZWKKRUPRQHRIDQDQLPDOVSHFLHV¶UHVSHFWLYHO\´
59.See generally Diamond v. Chakrabarty, 447 U.S. 303 (1980). 
60.  Id.
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tentable subject matter.61  In the opinion in Chakrabarty, Chief      
Justice Burger wrote to remind the USPTO that it and the courts 
³VKRXOG QRW UHDG LQWR WKH SDWHQW ODZV OLPLWDWLRQV DQG FRQGLWLRQV
ZKLFK WKH OHJLVODWXUH KDV QRW H[SUHVVHG´62  The Court determined 
that by its terms, the subject matter requirement of § 101 of the     
Patent Act was expansive in nature.63  This determination was based 
on the terminology used to define patentable subject matter, which 
XVHV WKH JHQHULF WHUPV ³PDQXIDFWXUH´ DQG ³FRPSRVLWLRQ RIPDWWHU´
WKDW³SODLQO\FRQWHmplate[] that the patent laws would be given wide 
VFRSH´64  Taking that reading of the Patent Act even further, the 
&RXUW DQQRXQFHG WKDW WKH VFRSH RI SDWHQWDEOH VXEMHFW PDWWHU ³
LQFOXGH>V@DQ\WKLQJXQGHUWKHVXQWKDWLVPDGHE\PDQ´65
The key to that holding, and why the challenge to the particular   
patent in question was made, turned on whether the genetically    
modified bacterium engineered to eat oil claimed in the patent was a 
³SURGXFWRIQDWXUH´´66  The Court made clear that the products and 
laws of nature are not patentable subject matter: 
The laws of nature, physical phenomena, and abstract ideas 
have been held not patentable. Thus, a new mineral  
discovered in the earth or a new plant found in the wild is not 
patentable subjecWPDWWHU³6XFKGLVFRYHULHVDUH
manifestations of . . . nature, free to all men and reserved  
H[FOXVLYHO\WRQRQH´67
However, the Court concluded that the bacterium in question was not 
a product of nature because the organism was only in existence due 
to the machinations of man, not nature.68  Therefore, the patent     
application claiming the bacterium was acceptable under the         
                                                                                                                          
61.Id.; Ricki Lewis, A Brief History of DNA Patents, DNA SCIENCE BLOG (June 
20, 2013), http://blogs.plos.org/dnascience/2013/06/20/a-brief-history-of-dna-
patents/, archived at http://perma.cc/JQN7-22P2. 
62.Chakrabarty, 447 U.S. at 308 (quoting United States v. Dubilier Condenser 
Corp, 289 U.S. 178 (1933)). 
63.Id. at 308-09 (1980). 
64.Id. at 308. 
65.Id. at 309 (citations omitted). 
66.Id. at 306. 
67.Id. at 309 (citations omitted). 
68. Id.
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expansive reading of patentable subject matter announced by the 
Court.69
After the Chakrabarty decision, the USPTO began granting many 
of the gene patent applications it received, eventually including    
patents claiming human genes.70  By 2005, the USPTO had issued 
patents granting exclusive rights to some 4,382 of the 23,688 genes 
that comprise the human genome.71  That is nearly twenty percent of 
the human genome that was reserved exclusively to their respective   
patent holders.72  The decision of the United States Supreme Court in 
Myriad put an end to the issuance of patents claiming naturally     
occurring DNA.73 However, it did leave intact the patents issued 
claiming cDNA and will allow future patent applications directed 
toward cDNA.74
IV. THE CONTROVERSY OF GENE PATENTS
Beginning with the first gene patent issued, there has been a fiery 
debate about the propriety of gene patents.75  Innovators have      
supported gene patents as a means to ensure that their research     
investment will be recouped.76  Opponents claim that gene patents 
violate patent law, the Constitution, and are against public policy as 
they allow corporDWHLQWHUHVWVWRPRQRSROL]HSHRSOH¶VDFFHVVWRWKHLU
own genetic information.77  Part IV details the claims on both sides 
of the debate to frame it as a legal, business, and social issue. 
                                                                                                                          
69. Id.
70.Torrance, supra note 32, at 176.
71.Kyle Jensen & Fiona Murray, supra note 8, at 239-240.
72.Some quick math would reveal that the amount of the human genome that had a 
patent claiming it by 2005 was 18.5%. 
73.See generally Myriad Genetics, Inc., 133 S.Ct. 2107. 
74.See id.
75.See generally BRCA FAQs, AMERICAN CIVIL LIBERTIES UNION, 
https://www.aclu.org/free-speech/brca-faqs (last visited Oct. 10, 2014), archived at
http://perma.cc/3FQ6-VZDF. 
76.See infra notes 118-138 and accompanying text. 
77.See infra notes 78-117 and accompanying text.
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A. Opposition to Gene Patents
1. Legal Arguments 
The opposition to gene patents comes from many groups who have 
various legal and social concerns regarding the propriety of these 
patents.78  The groups who oppose these patents include medical   
professionals, civil rights advocates, the American Association of 
Retired PersRQVWKH³$$53´DQGWKH6RXWKHUQ%DSWLVW&RQYHQWLRQ
to name a few. 79
Legal arguments claiming that DNA in molecular form should not 
be patent eligible subject matter under 35 U.S.C. § 101 were the most 
pervasive arguments of many opponents made in public statements 
and in various amicus briefs filed in support of AMP and the plain-
tiffs.80  The plaintiffs and their amicus made an argument under § 
101 that isolated-gene patents should be considered a product of   
nature, and, as discussed above, should not be eligible for patent    
protection.81
Regarding the § 101 issue, the AARP in its amicus brief to the 
)HGHUDO &LUFXLW DUJXHG WKDW ³'1$PROHFXOHV DQG KXPDQ JHQHV DUH
natural phenomena that when discovered are not the kind of         
µGLVFRYHU\¶WKDW6HFWLRQZDVGHVLJQHGWRSURWHFW´82  In its federal 
circuit amicus brief, the AARP cited American Wood-Paper Co. v. 
                                                                                                                          
78.SeeAMERICAN CIVIL LIBERTIES UNION supra  note 75. 
79.See Myriad Genetics, Inc. 133 S. Ct. at 2107.. (Plaintiff is the Association of 
Molecular Pathology, a group of clinical and research pathologists); see also Brief 
of Amici Curiae American Medical Association, et al, in Support of Petitioners, 
$VV¶QIRU0ROHFXODU3DWKRORJ\Y0\ULDG*HQHWLFV,QF6&W
(No. 12-398), 2013 WL 390998; Brief for AARP as Amici Curiae Supporting  
3HWLWLRQHUV$VV¶QIRU0ROHFXODU3DWKRORJ\Y8QLWHG6WDWHV3DWHQWDQG7UDGHPDUN
Office, 689 F.3d 1303 (Fed. Cir. 2011) (No. 2010-1406), 2011 WL 585711. Brief 
IRUWKH6RXWKHUQ%DSWLVW&RQYHQWLRQDV$PLFL&XULDH6XSSRUWLQJ3HWLWLRQHUV$VV¶Q
for Molecular Pathology v. United States Patent and Trademark Office, 653 F.3d 
1329 (Fed. Cir. 2011) (No. 2010-1406), 2011 WL 585712;AMERICAN CIVIL 
LIBERTIES UNION, supra note 75. 
80.See generally Myriad Genetics, Inc., 133 S. Ct. 2107.
81.See generally id.
82.%ULHIIRU$$53DV$PLFL&XULDH6XSSRUWLQJ3HWLWLRQHUV$VV¶QIRU0ROHFXODU
Pathology v. United States Patent and Trademark Office, 653 F.3d 1329 (Fed. Cir. 
2011) (No. 2010-1406), 2011 WL 585711, at *2. 
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Fiber Disintegrating Co., 90 U.S. 566 (1874), to analogize the      
LVRODWLRQ RI '1$ WR WKDW RI ³UHPRYLQJ SXOS IURP VWUDZ ZRRG RU
RWKHUQDWXUDOVRXUFHV´83  In American Wood-Paper Co., the Supreme 
&RXUW KHOG WKDW ³Perely removing pulp from straw, wood, or other 
natural sources did not make it a patentable new composition of    
PDWWHUµ$SURFHVVWRREWDLQLW>DQH[WUDFW@IURPDVXEMHFWIURPZKLFK
it has never been taken may be the creature of invention, but the thing 
LWVHOIZKHQREWDLQHGFDQQRWEHFDOOHGDQHZPDQXIDFWXUH¶´84  Thus, 
WKH WKUXVW RI WKH $$53¶V   DUJXPHQW LV WKDW ³>V@LPLODUO\
isolating a gene . . . from the human body does not then make the 
>JHQH@LWVHOISDWHQWDEOH´85
Additionally, the ACLU pointed to language in Chakrabarty that
also suggested human genes never should have been allowed to be 
patented.86  The ACLU considers that the passage from Chakrabarty
quoted above necessarily implies that human genes should not have 
been patentable.87  The DUJXPHQWJRHVPXFKOLNHWKH$$53¶V
argument: genes are analogous to a mineral or plant discovered in the 
wild and merely isolating them is not enough to make them patent 
eligible subject matter.88
2. Social Policies 
Many of the arguments opponents made against allowing human 
genes to be patented were made in regards to the social implications 
of gene patents.89  These concerns include restricting access to     
second opinions, discouraging genetic testing due to cost, and the 
potential to impede further research into the connections between 
certain gene sequences and disease states.90  Opponents have also 
                                                                                                                          
83.Id. at *3 (citing Wood Paper Patent, 90 U.S. 566 (1874)). 
84.Id. (quoting Wood Paper Patent, 90 U.S. 566 (1874)). 
85. Id.
86.AMERICAN CIVIL LIBERTIES UNION, supra note 75. 
87.See supra note 67 and accompanying text; AMERICAN CIVIL LIBERTIES UNION,
supra note 75. 
88.AMERICAN CIVIL LIBERTIES UNION, supra note 75. 
89.See infra notes 90-111 and accompanying text. 
90.See generally AMERICAN CIVIL LIBERTIES UNION, supra note 75. 
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claimed a moral, ethical, or religious disapproval regarding the     
patenting of genes.91
      a. Patient care 
In its amicus brief to the Federal Circuit, the AARP succinctly 
VXPPHGXSWKHSULPDU\FRQFHUQVUHODWHGWRSDWLHQWFDUH,W³XUJ>HG@
the Court to find the [BRCA patents] invalid . . . [because] patents 
such as [these] prohibit diagnosis and treatment based on second 
medical opinions and discourage full medical testing . . . [along with] 
DOVR VLJQLILFDQWO\ HOHYDW>LQJ@ WKH FRVW RI JHQHWLF WHVWLQJ´92  These 
assertions by the AARP are indicative of the opinion of many       
opponents of gene patents.93
As the AARP pointed out, patient care was often foremost among 
the social policy concerns of gene patent opponents.94  Thanks to the 
exclusivity granted to patent holders, gene patent holders could    
UHVWULFWRWKHUFRPSDQLHVIURPUXQQLQJGLDJQRVWLFVWRDQDO\]HSDWLHQWV¶
genetic makeup.95  In effect, this leaves patients without any access 
to a second opinion as to the diagnosis made by the patent holder 
genetic diagnostics laboratory, unless that patent holder agrees to 
license the gene patent or allow other laboratories to test for the    
individual gene that may indicate whether a patient is more likely to 
develop some disease.96  To illustrate this concern, opponents point 
to several cease and desist letters Myriad Genetics sent to university 
                                                                                                                          
91.See generally Audrey R. Chapman, Religious Contributions to the Debate on 
the Patenting of Human Genes, 10 U. ST. THOMAS L.J. 650 (2013). 
92.Brief for AARP as Amici Curia Supporting Petitioners, supra note 82, at 2. 
93.See generally Eric Hoffman, Why Gene Patents Are Bad for Patients and Sci-
ence, THE AMERICAN INTEREST (Aug.  9, 2011), http://www.the-american-
interest.com/articles/2011/8/9/why-gene-patents-are-bad-for-patients-and-
science/#sthash.MDvyTHBH.dpuf[http://perma.cc/FR5T-FMT6]. 
94.Brief for AARP as Amici Curiae Supporting Petitioners, supra note 82, at 3-4. 
95.Karuna Jaggar, Ruling to Overturn Human Gene Patents is a Huge Win For 
:RPHQ¶V+HDOWK, GENEWATCH,
http://www.councilforresponsiblegenetics.org/GeneWatch/GeneWatchPage.aspx?p
ageId=474, archived at http://perma.cc/6DFV-KCG3 (last visited Oct. 10, 2014). 
96. Id. 
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researchers who were testing for the BRCA genes in their not-for-
profit clinical laboratories.97
Gene patents could have also prevented the development of better 
and less expensive testing for patented genes due to the threat of   
infringement litigation.98  In a survey of genetic research labs,      
upward of fifty percent of those labs reported that the possibility of   
infringement actions concerning patented genes led them to          
discontinue research into some genes.99
Gene patents may also have provided physicians with incentives to 
violate the doctor-patient relationship.100  One illustration of this can 
be found in the story of a businessman from Washington.101  John 
Moore was diagnosed with hairy-cell leukemia.102  For treatment, he 
travelled from his home in Seattle, Washington to the UCLA Medical 
Center, where he was the patient of a top specialist in Oncology.103
+LVGRFWRURUGHUHGWKHUHPRYDORI0RRUH¶VVSOHHQDQGYDULRXVRWKHU
treatments.104
After treatment and surgery, Moore continued to travel to and from 
Los Angeles for the next seven years for continued testing.105  Moore 
thought he was being monitored for potential relapse and              
reappearance of his leukemia.106  What actually was happening     
bordered on the? His physician was filing patents that claimed unique 
FRPSRXQGVLQ0RRUH¶VEORRGDSDWHQWthat claimed one isolated gene 
RI0RRUH¶V DQG ZDV DOVR HQWHULQJ FRQWUDFWV WR GHYHORS D FHOO OLQH
XVLQJ 0RRUH¶V WLVVXH107  One contract with a pharmaceutical      
                                                                                                                          
97.E. Richard Gold & Julia Carbone, Myriad Genetics: In the Eye of the Policy 
Storm, 12 GENETICS  MED., S39, S39 ± S70 (2010). 
98.Hoffman,supra note 93.
99.Mildred K. Cho et al, Effects of Patents and Licenses on the Provision of Clini-
cal Genetic Testing Services, 5 J. MOLECULAR DIAGNOSTICS 3, 7 (February 2003). 
100.See infra notes 101-11 and accompanying text. 
101.See Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 480-81 (Cal. 1990). 
102.Id. 
103.Id. 
104.Id. 
105.Id.
106.Id.
107.Id. at 481-482. 
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company who wished to develop the cell line (named the Mo-cell 
line, after John Moore) was purportedly worth $15 million dollars.108
0RRUHVDLGDERXWWKHLQFLGHQW³:KDWWKHGRFWRUVKDGGRQHZDVWR
claim that my humanity, my genetic essence, was their invention and 
their property. They view me as a mine from which to extract       
biological material , ZDV KDUYHVWHG´109 As a result of this            
mistreatment, Moore filed a suit that was dismissed primarily for its 
XQXVXDO QDWXUH EXW 0RRUH¶V FDVH ZDV HYHQWXDOO\ KHDUG DQG WKH
California Court of Appeals ruled in his favor.110  However, the    
California Supreme Court eventually found that he had no property 
right in the patents and products derived from him, but only that he 
KDGPHULWRULRXVFODLPVDVWRWKHEUHDFKRIWKHUHVHDUFKHU¶VILGXFLDU\
duty to Moore and a failure of informed consent.111
b. Religious objections to gene patents 
Various religious figures and organizations have also been vocal 
opponents of gene patents.112  Their concerns with gene patents are 
not a unitary, monolithic voice, but have provided some viewpoints 
into the debate beyond the concerns for patients and the technical, 
scientific, and legal arguments against gene patents.113
Religious groups have raised concerns that the patenting of life 
IRUPVDQGWKHLUJHQHWLFFRGH³LPSOLHVWKDWKXPDQEHLQJVUDWKHUWKDQ
*RG DUH WKH LQYHQWRUV RI WKHVH IRUPV RI OLIH´114  This sentiment    
echoes the scientific argument against gene patents that the           
discoverers of valuable gene sequences are not actually inventing 
anything and, accordingly, should not be granted patent protection.115
A large group of faith-based organizations, which included 
Protestant, Catholic, Orthodox, Jewish, Muslim, Buddhist, and Hindu 
                                                                                                                          
108.Id. at 482 
109.John Vidal & John Carvel, Lambs to the Gene Market, THE GUARDIAN (Lon-
GRQ1RYDWTXRWLQJ-RKQ0RRUHVD\LQJKHZDV³HVVHQFH-UDSHG´
110.Moore, 793 P.2d at 502 
111.Id. at 497. 
112.See generally Audrey Chapman, supra note 91. 
113.See generally id.
114.Id. at 668. 
115.Rebecca S. Eisenberg, Why the Gene Patenting Controversy Persists, 77 
ACAD. MED., 1381, 1384.
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denominations, joined together to form the Joint Appeal Against 
Human and Animal Patenting.116  They released the following joint 
statement: 
We, the undersigned religious leaders, oppose the patenting of  
human and animal life forms. We are disturbed by the U.S. Patent 
2IILFH¶V UHFHQW GHFLVLRQ WR SDWHQW KXPDQ ERG\ SDUWV DQG VHYHUDO
genetically engineered animals. We believe that humans and animals 
are creations of God, not humans, and as such should not be patented 
as human inventions.117
B. Proponents of Gene Patents 
1. Legal Arguments 
Proponents of gene patents alleged that, as patented, genes were 
not products of nature.118  This argument flows from the fact that 
composition of matter patents had been granted to substances that 
were isolated and purified from their source.119  Judge Learned Hand, 
in Parke-Davis & Co. v. H.K. Mulford Co., explained the isolation 
and purification doctrine.120 In that case, the patentee had claimed 
ownership over the chemical compound adrenaline.121  By claiming 
the chemical, the patentee was able to exert exclusivity over a    
chemical compound that occurs naturally in all people122
He was able to do so because, as Judge Hand found, the claimed 
substance was different in chemical compound, due to its separation 
from the gland producing it, and because of its therapeutic effect, 
which results from the concentration of the chemical and the removal 
                                                                                                                          
116.Chapman, supra note 91 at 662-63. 
117.Joint Appeal Against Human and Animal Patenting, text of the press confer-
ence announcement made available by the General Board of Church and Society of 
the United Methodist Church, Washington, D.C. (May 17, 1995).
118.Kevin Noonan, Why Genes Must Remain Eligible For Patenting, GENEWATCH
http://www.councilforresponsiblegenetics.org/GeneWatch/GeneWatchPage.aspx?p
ageId=304&archive=yes, archived at http://perma.cc/7C3S-PKED. 
119.See generally Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95 (S.D.N.Y. 
1911); see also Merck & Co v. Olin Mathieson Chemical Corp, 253 F.2d 156 (4th 
Cir. 1958). 
120.See Parke-Davis & Co. at 103. 
121.Id. at 95. 
122.Id.
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of other substances.123  Judge Hand described the differences made 
E\LVRODWLQJDQGSXULI\LQJDGUHQDOLQHDVDGLIIHUHQFH³QRW LQGHJUHH
EXW LQ NLQG´124  Thus, the isolation and purification doctrine of  
chemical compound patents allows for the patenting of some        
naturally occurring substances after all.125
-XGJH+DQG¶VDQDO\VLVEROVWHUVWKHDUJXPHQWRISURSRQHQWVRIJHQH
patents by the fact that mosWJHQHWLFVHTXHQFHFRQWDLQSULPDULO\³MXQN
'1$´DVGHWDLOHGLQ3DUW,,DQGQHFHVVDULO\UHTXLUHLVRODWLRQRIWKH
active exon to be useful in a laboratory setting.126 Furthermore, to be 
XVHIXO E\ GLDJQRVWLFV FRPSDQLHV JHQH VHTXHQFHV DUH ³SXULILHG´ E\
removiQJWKH³MXQN´DQGFUHDWLQJF'1$127  However, the claim that 
cDNA is the more useful version of the gene sequence seems to    
ignore the fact that innovator labs largely held patents that claimed 
the naturally occurring genomic DNA that are the source for 
cDNA.128
There is also the fact that to disallow the patenting of genes would 
upset thirty years of patent policy in the United States.129  The        
potential for economic chaos for the industry in the absence of gene 
patents was central to the argument.130  Proponents of gene patents 
also pointed to the potential that, if human gene patents were invalid, 
then it may be that any number of antibiotics, petroleum, and animal 
products are ineligible for patent protection.131
                                                                                                                          
123.Id. at 104. 
124.Id. at 103. 
125.See generally id. at 95.  ;see also Merck & Co, 253 F.2d 156. 
126.See OAK RIDGE NATIONAL LABORATORIES, supra note 31, at BB5 
127.See supra notes 47 - 49 and accompanying text. 
128.Andrew Pollack, After Patent Ruling, Availability of Gene Tests could Broad-
en, NEW YORK TIMES, June 13, 2013, 
http://www.nytimes.com/2013/06/14/business/after-dna-patent-ruling-availability-
of-genetic-tests-could-broaden.html?pagewanted=all&_r=0, archived at
http://perma.cc/RL53-MQY4. 
129.$VV¶QIRU0ROHFXODU3DWKRORJ\Y86372, 702 F. Supp. 2d 181, 220 (S.D.N.Y. 
2010).
130.Noonan, supra note 118. 
131.Id.
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2. Research Incentive 
The proponents of gene patents also refute the idea that gene       
patents create a monopolization of genetic information by inhibiting 
researchers other than the patent holder from conducting research.132
Kevin Noonan, a partner at McDonnel Boehnen Hulbert & Berghoff 
LLP, claims that the opposite may in fact be the case.133  He points to 
the increase in the number of basic research reports on the genes in 
question in Myriad (BRCA1 and BRCA2) since the patents claiming 
the genes were issued.134  As well, Noonan cites to multiple studies 
FRQGXFWHGLQWKHHDUO\¶VLQWKH8QLWHG6WDWHV$XVWUDOLD-DSDQ
and Germany that indicate gene patents rarely affect the research of 
academic scientists.135
Noonan goes on to claim that the patent incentive has actually    
encouraged private research companies to accelerate their research 
into genetics.136  The result of such acceleration may very well be an 
increase in the rate of discovery of the genetic markers that indicate 
DQLQGLYLGXDO¶VSRWHQWLDOWRGHYHORSFHUWDLQ diseases.137  He and other 
proponents of gene patents argue that when research is competitive 
then patients win in the end, because knowledge of their genetic    
information and the possibility of a more quickly available diagnostic 
or treatment results in better outcomes for them.138
V. MYRIAD: FROM NEW YORK TO D.C. 
The primary legal issue in dispute in the string of Myriad decisions 
was whether isolated genomic and complementary DNA sequences 
were patentable subject matter under § 101 of the United States    
Patent Act.139  There were also several method claims involved in the 
lower court proceedings, which are not relevant to the discussion of 
                                                                                                                          
132.Id.
133.Id.
134.Id.
135.Id.
136 Id.
137.Id.
138.Id.
139.See $VV¶QIRU0ROHFXODU3DWKRORJ\Y86372)6XSSG6'1<
2010).
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the gene patents, as those patents concerned various methods by 
which Myriad was determining whether a potential therapeutic agent 
was effective in treating cancer.140  Those method patents will be   
discussed in Part VI. 
The case that eventually reached the Supreme Court began in    
federal district court in the Southern District of New York.141  The 
district court decided in favor of the plaintiff and issued an opinion 
LQYDOLGDWLQJ0\ULDG¶VSDWHQWVDVVXEMHFWPDWWHUXQSDWHQWDEOHXQGHU
101 of the Patent Act.142  Myriad appealed to the United States Court 
RI $SSHDOV IRU WKH )HGHUDO &LUFXLW WKH ³)HGHUDO &LUFXLW´ ZKLFK
reveUVHG WKH ORZHUFRXUWGHFLVLRQDQGKHOG WKDW0\ULDG¶VSDWHQWVRQ
the BRCA1 and BRCA2 gene were valid as to both genomic and 
complementary DNA.143 Upon a writ of certiorari, the Supreme 
Court of the United States heard the case.  In a unanimous opinion 
penned by Justice Thomas, the Court reversed the Federal Circuit in 
part and affirmed in part. 
A. Southern District of New York 
³7KHLQTXLU\LQWRDQLQYHQWLRQ¶VSDWHQWHOLJLELOLW\LVDIXQGDPHQWDO
RQHDQGDVVXFKµWKHREOLJDWLRQWRGHWHUPLQHZKDWW\SHRIGLVFRYery 
is sought to be patented must precede the determination of whether 
WKDW GLVFRYHU\ LV LQ IDFW QHZ RU REYLRXV¶´144  This is merely a 
statement of the § 101 standard that patent eligibility is the threshold 
                                                                                                                          
140.See id.
141.See id.
142.See id.
143.$VV¶QIRU0ROHFXODU3DWKRORJ\Y863DWHQW	 Trademark Office, 653 F.3d 
1329, 1358 (Fed. Cir. 2011); see also $VV¶QIRU0ROHFXODU3DWKRORJ\Y8QLWHG
States Patent and Trademark Office, 689 F.3d 1303, 1337 (Fed. Cir. 2012) (af-
ILUPHGFRXUW¶VGHFLVLRQWRH[HUFLVHGHFODUDWRU\MXGJPHQWMXULVGLFWLRQRYHU this case, 
UHYHUVHGWKHGLVWULFWFRXUW¶VJUDQWRIVXPPDU\MXGJPHQWZLWKUHJDUGWR0\ULDG¶V
FRPSRVLWLRQFODLPVWRLVRODWHG'1$VDQGDIILUPHGWKHGLVWULFWFRXUW¶VJUDQWRI
VXPPDU\MXGJPHQWZLWKUHJDUGWR0\ULDG¶VPHWKRGFODLPVGLUHFWHGWRFRPSDULQJ
or analy]LQJJHQHVHTXHQFHVDQGUHYHUVHGWKHGLVWULFWFRXUW¶VJUDQWRIVXPPDU\
MXGJPHQWZLWKUHJDUGWR0\ULDG¶VPHWKRGFODLPWRVFUHHQLQJSRWHQWLDOFDQFHU
therapeutics via changes in cell growth rates of novel, man-made transformed 
cells). 
144.$VV¶QIRU0ROHFXOar Pathology, 702 F. Supp. 2d at 219 (quoting Parker v. 
Flook, 437 U.S. 584, 593 (1978)). 
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question regarding the validity of a patent and must be answered  
before continuing on to other legal matters regarding the patent in         
question.145 The District Court determined that the question regarding 
0\ULDG¶V %5&$ JHQH SDWHQWV ZDV ³ZKHWKHU WKH FODLPHG              
compositions and methods constitute statutory subject matter or fall 
within the judicially created products of nature exception to          
SDWHQWDEOHVXEMHFWPDWWHU´146
)LUVWWKHFRXUWGLVPLVVHG0\ULDG¶VLQLWLDOGHIHQVHVWRWKHFODLPRI
ineligibility.147 0\ULDG¶VILUVWDUJXPHQWZDV that the court should not 
look to invalidate their gene patents on the grounds that the      
³µFDUHIXOO\FRQVLGHUHGSROLF\RIWKH86372¶LVµHQWLWOHGWRJUHDW
UHVSHFW IURP WKH FRXUWV¶´ EDVHG RQ WKH SUHVXPSWLRQ RI YDOLGLW\ RI
SDWHQWV DQG WKH 86372¶V consideration of the eligibility of gene    
patents.148  This argument did not sway the court and it pointed to a 
)HGHUDO &LUFXLW GHFLVLRQ LQ VD\LQJ WKDW ³>WKDW FRXUW@ KDV SUHYLRXVO\
KHOG WKDW LWRZHVQRGHIHUHQFH WR86372OHJDOGHWHUPLQDWLRQV´DQG
WKDW ³>Whe] court reviews statutory interpretation . . . without          
GHIHUHQFH´149
7KH FRXUW¶V DQDO\VLV SURYLGHG WKDW 0\ULDG¶V JHQH SDWHQWV DV
FODLPHGKDGQR³PDUNHGO\GLIIHUHQWFKDUDFWHULVWLFV´IURPDSURGXFW
RI QDWXUH GHVSLWH0\ULDG¶V DVVHUWLRQ WKDW WKH isolation of the DNA 
molecules should render them patentable.150  Focusing on the nature 
of DNA, the court determined that regardless of whether the DNA is 
native or isolated its primary function is to carry genetic                
information.151  Due to this functional concern, the Court decided 
LVRODWHG'1$GRHVQRW KDYH WKH UHTXLVLWH ³GLIIHUHQW FKDUDFWHULVWLFV´
                                                                                                                          
145.See In re %LOVNL)G)HG&LUHQEDQF³:KHWKHUD
claim is drawn to patent-eligible subject matter under § 101 is a threshold inquiry, 
and any claim of an application failing the requirements of § 101 must be rejected 
HYHQLILWPHHWVDOORIWKHRWKHUOHJDOUHTXLUHPHQWVRISDWHQWDELOLW\´
146.$VV¶QIRU0ROHFXODU3DWKRORJ\, 702 F. Supp. 2d at 220. 
147.Id.
148.Id.
149.Id. at 221 (quoting Arnold 3¶VKLSY'XGDV)G)HG&LU
2004)). 
150.$VV¶QIRU0ROHFXODU3DWKRORJ\, 702 F. Supp. 2d at 227-228. 
151.Id. at 227-229. 
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to allow patentability.152 0\ULDG¶V F'1$ FODLPV ZHUH DOVR IRXQG
LQYDOLGGXHWRWKHFRXUW¶VGHWHUPLQDWLRQWKDWGHVSLWHFRQWDLQLQJRQO\
exons, cDNA is QRW³PDUNHGO\GLIIHUHQW´IURPQDWLYH'1$153
Myriad also asserted that the invalidation of their patents would 
FRPSULVHDQXQFRQVWLWXWLRQDO WDNLQJZKLFKWKHFRXUWFDOOHG³QRYHO´
EXW³XQSHUVXDVLYH´154 7KLVZDVDOVRWKH&RXUW¶VDQDO\VLVFRQFHUQLQJ
0\ULDG¶V Sroposition that invalidating the patents would be in         
violation of the treaty obligations of the United States as embodied in 
the Agreement on Trade-Related Aspects of Intellectual Property 
5LJKWV³75,36´155
B. The Federal Circuit: Round One 
On appeal, the Federal Circuit affirmed the District Court in part 
and reversed the District Court in part.156  The Federal Circuit       
DIILUPHG WKH ORZHU FRXUW¶VGHFLVLRQV UHJDUGLQJ WKHPHWKRGVSDWHQWV
and reversed the decisions on the composition patents, which it found 
were directed to patent eligible subject matter as to both the native 
DNA and cDNA claims.157  In finding that the composition of matter 
patents was valid, the court relied on the totality of the differences 
between native DNA and isolated DNA, rather than the more strict 
functionally informational approach the District Court used.158
However, the Federal Circuit had the chance to hear the case again 
when the Supreme Court granted certiorari and remanded the case 
back to the court to review its decision in light of the Supreme 
                                                                                                                          
152.Id. DW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native DNA as it exists in nature, it constitutes unpatentable subject matter under 
86&´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ity diagnostic, therapeutic, or surgical methods as well as particular inventions on 
the grounds of pXEOLFLQWHUHVW´
156.$VV¶QIRU0ROHFXODU3DWKRORJ\, 653 F.3d at 1358. 
157.Id.
158.Id. at 1350-³>,@WLVWKHGLVWLQFWLYHQDWXUHRI'1$PROHFXOHVDVLVRODWHG
compositions of matter that determines their patent eligibility rather than their 
physiological XVHRUEHQHILW´
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&RXUW¶V GHFLVLRQ LQ Mayo Collaborative Services v. Prometheus    
Laboratories, Inc.159  
C. The Federal Circuit: Round Two 
On remand, the Federal Circuit maintained its position regarding 
all the claims in question.160  However, in this decision the court 
made a definitive statement on the patent eligibility of cDNA.161  The 
FRXUWKHOGWKDW³WKHFODLPHGF'1$VDUHHVSHFLDOO\GLVWLQFWLYHODFNLQJ
the non-coding introns present in naturally occurring chromosomal 
DNA.  They are even more the result of human intervention into    
nature and are hence patent-HOLJLEOHVXEMHFWPDWWHU´162
D. The Supreme Court 
In June 2013, the Supreme Court delivered an opinion that          
LQYDOLGDWHG0\ULDG¶VJHQHSDWHQWVDQGDOORWKHUJHQHSDWHQWVFODLPLQJ
native or genomic DNA, but maintained the validity of cDNA      
patents.163
The Court sided with the District Court in determining that the    
native DNA patents were invalid due to their functionally             
informational value as demonstrated by the claims in the patents   
³IRFXV RQ WKH JHQHWLF LQIRUPDWLRQ HQFRGHG LQ WKH >JHQHV@´164 On 
cDNA, the Court clarified that cDNA patents remain valid as         
patentable subject matter because of the fact that human intervention 
is required to make the molecule.165
The Court specifically addressed issues that were not implicated in 
its decision, which reveal some means by which innovator research 
                                                                                                                          
159.$VV¶QIRU0ROHFXODU3DWKRORJ\Y8QLWHG6WDWHV3DWHQWDQG7UDGHPDUN2IILFH
132 S.Ct. 1794 (Memo) (2012); see Mayo Collaborative Services v. Prometheus 
Laboratories, Inc., 132 S.Ct. 1289 (2012) (concerning the validity of certain meth-
ods patents). 
160.$VV¶QIRU0ROHFXODU3DWKRORJ\, 689 F.3d at 1337. 
161.Id. at 1329. 
162.Id.
163.Myriad Genetics, Inc.6&WDW³:HPHUHO\KROGWKDWJHQHVDQGWKH
information they encode are not patent eligible under § 101 simply because they 
have beHQLVRODWHGIURPWKHVXUURXQGLQJJHQHWLFPDWHULDO´
164.Id. at 2118. 
165.Id. at 2119. 
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and diagnostics labs may still have some patent claims to their      
discoveries.166  Justice Thomas specifically noted that certain types of 
method claims might still be patentable.167  Additionally, patents that 
LQYROYH ³QHZ DSSOLFDWLRQV RI NQRZOHGJH DERXW    JHQHV´ DUH WR
remain patentable subject matter.168  Lastly, there is the possibility 
that DNA in which the nucleotide order has been altered in some way 
may be patent eligible subject matter.169
VI. WHAT¶S LEFT: INCENTIVES FOR INNOVATION AND 
COMPETITION POST-MYRIAD
As has been detailed above, there are various grounds on which 
people and organizations opposed the patenting of human genes.170
Supporters generally relied upon not upsetting the status quo and the 
argument that without gene patents there would remain little          
incentive for crucial genetic research.171  There are no legitimate   
parties arguing that research into the human genetic code and             
discovering the connection between genetics, diseases, and potential 
therapies is not a desirable course of action, but why should research 
labs and diagnostics companies continue to fund such ventures    
without the security afforded by gene patents?  This Part of the Note 
outlines several means by which innovators may still be incentivized, 
including federal funding, other types of patents and patent protection 
in other markets. Additionally, this Note suggests the adoption of a 
proposed regulatory change that would have genetic diagnostics be 
regulated by the FDA and would afford some exclusivity to innovator 
labs under current regulatory exclusivity regimes. 
                                                                                                                          
166.Id.
167.Id.
168.Id. 
169.Id. ³6FLHQWLILFDOWHUDWLRQRIWKHJHQHWLFFRGHSUHVHQWVDGLIIHUHQWLQTXLU\DQG
we express no opinion about the application of § 101 to such endeDYRUV´
170.See supra, Part III. 
171.See supra Part III.
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A. Remaining Patent Protection 
1. cDNA Patents 
The hROGLQJ LQ WKH 6XSUHPH &RXUW¶V GHFLVLRQ LQMyriad leaving   
intact the viability of cDNA patents is key to the remaining incentive 
scheme for genetic researchers.172  Complementary DNA is generally 
viewed as the more commercially viable form of DNA.173  This is 
because cDNA is the more easily manipulated form of DNA that is 
used to engineer plant, animal, and bacterial cells.174  In addition, 
cDNA is the form of DNA used in most of the commercially       
available diagnostics due to the ability to synthesize more of, and 
thus amplify, the specific gene at which the diagnostic is targeted.175
However, a significant problem with continuing to rely on cDNA 
patents for protection in the genetics field was not addressed by the 
Supreme Court in Myriad.  Due to the advanced state of genetics 
technology and the widespread understanding of the process by 
which cDNA is synthesized, cDNA patents may very well be        
successfully challenged under § 103 for being obvious to a person 
skilled in the art.176
2. Methods Patents 
Some types of patents are likely to remain viable in the genetics 
field for quite some time, and were specifically singled out by the 
Supreme Court as potential sources of patent protection for genetic 
researchers.177 -XVWLFH7KRPDVH[SODLQHGWKDW³>K@DG0\ULDGcreated 
an innovative method of manipulating genes while searching for the 
BRCA1 and BRCA2 genes, it could possibly have sought a method 
SDWHQW´178  Based on this guidance from the Court, innovator diag-
nostics companies may be secure in the knowledge that if they do 
                                                                                                                          
172.Myriad Genetics, Inc., 133 S.Ct. at 2119. 
173.Pollack, supra note 128. 
174.Id.
175.Gregory Dolin, Exclusivity Without Patents: The New Frontier of FDA      
Regulation for Genetic Materials, 98 IOWA L. REV. 1399, 1415 (2013). 
176.Id. at 1444; The obviousness problem with continuing to allow cDNA patents 
cannot be understated. 
177.Myriad Genetics, Inc., 133 S.Ct. at 2119. 
178.Id.
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devise some novel method of gene manipulation, they will be able to 
secure a patent for the innovation, so long as they can demonstrate 
that the claimed innovation meets the necessary requirements of    
patentability. 
Furthermore, Myriad itself won a challenge to one of its method 
SDWHQWV LQ WKH OLWLJDWLRQ OHDGLQJ XS WR WKH 6XSUHPH &RXUW¶V            
decision.179  The method patent that was unsuccessfully challenged 
concerned a method by which Myriad was determining the efficacy 
of certain potential cancer treatments.180  The claimed innovation was 
challenged on the basis that it was simply applying a law of nature 
that cancer cells do not grow as well in the presence of an             
oncological therapy.181  This challenge seemed to be a good          
argument against the claimed method under the decision made by the 
Supreme Court in Mayo Collaborative Services v. Prometheus      
Laboratories, Inc.. ,Q WKDW FDVH WKH &RXUW ³LQYDOLGDWHG FODLPV
directed to the relationship between concentrations of certain        
metabolites in the blood and the likelihood that a particular dosage of 
D WKLRSXULQH GUXJ ZLOO EH RSWLPXP´182 7KH &RXUW KHOG WKDW ³WR
transform an unpatentable law of nature into a patent-eligible        
application of such a law, one must do more than simply state the 
ODZRIQDWXUHZKLOHDGGLQJWKHZRUGVµDSSO\LW¶´183
Using the Mayo standard, the Federal Circuit decided that Myriad 
had supplied a sufficiently innovative step to avoid the natural law 
problem.184  The rHDVRQLQJRIWKHFRXUWZDVWKDWRQFHD³FRPSRVLWLRQ
of matter is [determined to be] patent eligible subject matter,         
applying various known types of procedures to it is not merely     
DSSO\LQJFRQYHQWLRQDOVWHSVWRDODZRIQDWXUH´185
                                                                                                                          
179.$VV¶QIRU0ROHFXODU3DWKRORJ\, 689 F.3d at 1309. 
180.Id. at 1310. 
181.Id. . 
182.Id. at 1336 (quoting Mayo Collaborative Services v. Prometheus Laboratories, 
Inc., 132 S. Ct 1289, 1294 (2012)). 
183.Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct 1289, 
1290 (2012). 
184.$VV¶QIRU0ROHFXODU3DWKRORJ\, 689 F.3d at 1335-1336. 
185.Id. DW³7KHWUDQVIRUPHGPDQ-made nature of the underlying subject 
matter in claim 20 makes the claim patent-eligible. The fact that the claim also 
LQFOXGHVWKHVWHSVRIGHWHUPLQLQJWKHFHOOV¶JURZWKUDWHVDQGFRPSDULQJJURZWK
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However, despite its success on the aforementioned method claim,     
Myriad has more recently been the victim of some method patent 
invalidations at the hand of the Federal Circuit.186  In In re BRCA1,
the Federal Circuit invalidated a method claim for comparing a      
persRQ¶V %5&$ VHTXHQFH ZLWK ZLOG-type BRCA sequences to       
identify differences that may indicate an increased risk of breast   
cancer.187  Additionally, the court invalidated another method claim 
for some diagnostic methods used to identify mutations in BRCA 
sequences, because the claimed steps and diagnostic methods did not 
contain any new process, design, or use of diagnostic tests or        
instruments.188
As can be seen in recent court decisions, there are certainly more 
hurdles to successfully claiming a method in a patent.189 However, 
the option is still available to genetic researchers and diagnostic    
innovators if they can clear those hurdles. 
3. Gene Patent Protection Abroad 
Despite no longer being able to patent naturally occurring genes in 
the United States, innovator researchers and diagnostic companies 
still have the option to apply for patent protection for discovered 
genes in countries that allow for the patenting of such genes.190
Naturally occurring gene patents are still viable in at least three of the 
largest healthcare markets in the world: the European Union, Japan, 
                                                                                                                          
rates does not change the fact that the claim is based on a man-made, non-naturally 
occurring transformed cell²SDWHQWHOLJLEOHVXEMHFWPDWWHU´
186.In the time between the Mayo and Myriad decisions and this case, the Supreme 
Court decided Alice Corp. v. CLS Bank ,QW¶O, 134 S.Ct. 2347 (2014), which rein-
forced a two-step test to determine patent eligibility for claims containing abstract 
ideas; see In re BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litig., 
774 F.3d 755,756 (2014) (citing Alice to establish that the two-step test requires 
identifying whether the claim contains an abstract idea and then determining 
whether there are other items in the claim that may render it patent eligible despite 
containing an abstract idea). 
187.In re BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litig., 774 
F.3d 755, 756 (2014). 
188.Id. at 766. 
189.See supra notes 177-188 and accompanying text. 
190.See infra notes 191-204 and accompanying text. 
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and Australia.191  There are also other countries in which gene patents 
remain valid, but this Note only addresses the possibility of securing 
gene patents in these three countries.192
7KH(XURSHDQ3DWHQW2IILFH³(32´DFWLQJXQGHUWKHMXULVGLFWLRQ
of the European Patent Organization, allows the patenting of genes 
following the guidelines of European Union directive 98/44/EC (the 
³%LRWHFK 'LUHFWLYH´193  The Biotech Directive provides that        
³ELRORJLFDOPDWHULDOZKLFKLVLVRODWHGIURPLWVQDWXUDOHQYLURQPHQWRU
produced by means of a technical process may be the subject of an 
LQYHQWLRQHYHQLILWSUHYLRXVO\RFFXUUHGLQQDWXUH´194  However, the 
EPO will not grant patents directed to genes identified without an 
identified function.195  Along with an identifiable function, the gene 
PXVWDOVRKDYHDGLVFORVHG³LQGXVWULDODSSOLFDWLRQ´OLVWHGLQWKHSDWHQW
application.196 ³,QGXVWULDO DSSOLFDWLRQ´ KDV KDG YDULRXV                 
interpretations applied to it, but a recent decision by the EPO        
GHWHUPLQHG WKDW RQO\ D ³FRQFUHWH EHQHILW´ LV UHTXLUHG197  For         
example, a gene shown to be usable in the cure or diagnosis of a   
disease would be likely considered to have an immediate benefit to 
industry even though it may be profitable for any use.198  A gene that 
shows promise that future research will lead to such a practical     
application will be insufficient to gain patentability.199  This includes 
                                                                                                                          
191.See Infra notes 192-204 and accompanying text. 
192.See generally Executive Summary: Genetics, genomics, and the patenting of 
DNA, WORLD HEALTH ORGANIZATION, available at 
http://www.who.int/genomics/publications/background/en/, archived at 
http://perma.cc/4342-8HG3 (discussing the patenting of genes around the world 
and noting that genes can be patented in India, China, and potentially Brazil). 
193.Andrew Sharples, Gene Patents in Europe Relatively Stable Despite           
Uncertainty in the U.S., GENETIC ENGINEERING & BIOTECHNOLOGY NEWS (Mar. 
23, 2011), http://www.genengnews.com/insight-and-intelligenceand153/gene-
patents-in-europe-relatively-stable-despite-uncertainty-in-the-u-
s/77899385/,archived at http://perma.cc/PP7W-HH9N. 
194.Council Directive 98/44, art. 3, 1998 O.J. (L 213) 13,18. 
195.Id. at 15. 
196.Id. at 18. 
197.Sharples, supra note 193. 
198.Naomi Hawkins, Human Gene Patents and Genetic Testing in Europe: A  
Reappraisal, 7:3 SCRIPTed 453, 461 (2010), http://www.law.ed.ac.uk/ahrc/script-
ed/vol7-3/hawkins.asp. 
199.Id.
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any claims that are speculative as to possible future uses.200  Under 
these guidelines, many of the genes that researchers and diagnostic 
companies would have patented in the United States should remain 
patentable in the European Union. 
,Q  WKH -DSDQHVH 3DWHQW 2IILFH WKH ³-32´ LQFOXGHG as        
patentable subject matter methods by which information can be   
gathered from the human body.201  This guideline will clearly apply 
to the patenting of genetic material that may indicate possible disease 
states in a person.202  However, the claim to the gene or DNA       
sequence must be carefully drawn to avoid including any step that 
LQYROYHV MXGJPHQW GLDJQRVLV RU WUHDWPHQW RI D SHUVRQ¶V SK\VLFDO
VWDWHEHFDXVHWKHFODLPZLOOWKHQIDLOXQGHUWKH-32¶VUXOHVH[FOXGLQJ
FODLPVWR³PHGLFDODFWLYLW\´203
Finally, in Australia, courts that have had the opportunity to hear 
challenges to gene patents have simply dismissed the cases, and the 
higher courts have denied rehearing of the cases.204  As such, gene 
patents are still viable in Australia. 
B. Academic Pursuits and Federal Funding 
Regardless of patent protection, academic research facilities have 
long been a bastion of scientific advancements.  As evidence of this, 
much of modern knowledge has been developed without any        
incentive beyond the accumulation of raw knowledge about the 
world, how it works, and ways in which humans can manipulate the 
natural order in productive ways. 
In light of the fruitfulness of academic research, the federal       
government provides large amounts of funding for research into   
various fields of study, including various forms of genetic             
                                                                                                                          
200.Id. 
201.Kenji Sugimaura & Rebecca Chen, IPS Cell Technology Spurs Biological  
Patenting in Japan, World Intellectual Property Review Annual 2013, at 66, 67 
(2013), http://sugi.pat.co.jp/wp-content/uploads/2013/05/WIPR-2013-
Annual_Page_1.pdf, [http://perma.cc/BXJ5-5ZXV]. 
202.Id.
203.Id.
204.Heidi Ledford, Australian Gene-Patent Case Dismissed, NATURE NEWS
BLOG (SEP. 5, 2014, 18:46 BST), http://blogs.nature.com/news/2014/09/australian-
gene-patent-case-dismissed.html, archived http://perma.cc/F5TQ-J3Y4.
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research.205  In 2013, the National Institutes of Health reported that 
federal funding for genetics research, including categories such as 
³*HQH7KHUDS\´³*HQH7KHUDS\&OLQLFDO7ULDOV´³*HQHWLF7HVWLQJ´
DQGDEURDG³*HQHWLFV´FDWHJRU\H[FHHGHGHLJKWELOOLRQGROODUV206
Genetic diagnostic companies may decide that, without adequate 
patent protection, that their business model may be better suited to 
simply developing the actual diagnostics used to commercialize the 
findings of academic researchers.  This model would allow these 
companies to funnel their former research costs into the development 
of better diagnostics, which may lead to more commercial success 
because they can focus on supplying the best product rather than  
racing to find the next BRCA-W\SH³JROGPLQH´
C. Regulatory Schemes 
The FDA has the authority to regulate genetic tests, but does not 
currently do so except for genetic test kits.207  Test kits are            
diagnostics marketed as a commercial test sold directly to consumers 
or labs other than the lab that developed the test.208  On the other 
KDQGODERUDWRU\GHYHORSHGWHVWV³/'7V´DUHGLDJQRVWLFVGHYHORSHG
and performed by only the single innovator lab to which all specimen 
samples, regardless of collection site, are sent for testing.209  The 
FDA does not currently regulate the validation or performance of 
LDTs.210  However, the FDA has provided Congress with draft 
guidelines on the regulation of LDTs.211  As no decisions have been 
                                                                                                                          
205.See generally Estimates of Funding for Various Research, Condition, and Dis-
ease Categories (RCDC), NATIONAL INSTITUTES OF HEALTH (Feb. 5, 2015), 
http://report.nih.gov/categorical_spending.aspx, archived at http://perma.cc/Z47V-
BNBK (describing the amount of money funneled into various areas of research). 
206.Id.
207.Regulation of Genetic Tests, NATIONAL INSTITUTES OF HEALTH (Apr. 
17, 2015), http://www.genome.gov/10002335, archived at http://perma.cc/EB7J-
MWPS. 
208.Id. 
209.Id. 
210.Id.; See also Dolin, supra note 175, at 1456-57 (showing that validation means 
the determination that a diagnostic test performs adequately the function for which 
it was designed to be used). 
211.See generally Laboratory Developed Tests, FOOD AND DRUG 
ADMINISTRATION, 
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made in regards to the full implementation of those guidelines, this 
Note does not address the contents of those proposed guidelines.  
However, this Note does propose that the FDA should extend their 
current regulatory exclusivity scheme to cover LDTs and test kits and 
provide an exclusivity-based incentive for genetic research.  This 
Note has identified one promising scheme proposed by Dr. Gregory 
Dolin. 
Gregory Dolin, M.D., proposes that an expansion in the law that 
controls biologic drug products would help incentivize research into 
genetic diagnostics even in the absence of patent claims.212  He     
proposes that the non-patent market exclusivity regime that is       
currently in effect for biologic drug products could easily be         
extended to include genetic diagnostics classified as either LDTs or 
test kits.213  This kind of market exclusivity would not be a barrier to 
research into or the development of new treatments or diagnostics 
that use the same gene sequences because his proposed scheme 
would only provide exclusivity to the marketer of tests intended to 
treat, cure, or diagnose a targeted disease.214  Therefore, other       
researchers may freely use the identified genes in developing their 
own diagnostics or treatments for the same or other disease           
associated with that specific genetic sequence.215 The application of 
the regulatory exclusivity regime will determine when the innovator 
will lose exclusivity, but FDA market exclusivity, which is variable 
in length, is generally far shorter than the twenty years of control 
granted by a patent.216
D. Trade Secret 
If the FDA declines to create or extend to LDTs some form of  
regulatory exclusivity, diagnostics companies still have the option to 
UHWDLQWKHLUWHVWUHVXOWVDVDIRUPRIWUDGHVHFUHW$WUDGHVHFUHWLV³>D@
formula, process, device, or other business information that is kept 
                                                                                                                          
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagn
ostics/ucm407296.htm, archived at http://perma.cc/47YG-JGJP. 
212.Dolin, supra note 175, at 1406.
213.Id. at 1399-1400. 
214.Id. at 1459. 
215.Id. 
216.Id. at 1460.
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confidential to maintain an advantage oYHU FRPSHWLWRUV´217
However, the Uniform Trade Secrets Act (UTSA) provides that to be 
SURWHFWDEOH WKH LQIRUPDWLRQ PXVW QRW EH ³JHQHUDOO\ NQRZQ RU        
DVFHUWDLQDEOH´ZKLFKPDNHV LW XQOLNHO\ WKDW D GLDJQRVWLFV FRPSDQ\
would be able to bring a state law claim under the UTSA.218  That is 
why this Note describes this method of maintaining competitive   
advantage as a form of trade secret. 
As a diagnostic laboratory conducts more tests, the lab will          
invariably accrue more knowledge about the amount and type of  
existing polymorphs of the gene that is the focus of the diagnostic.219
Knowledge of the resulting disease rates correlated with certain    
polymorphs will allow that lab to more accurately establish the     
potential for a specific client to develop the disease associated with 
abnormalities within that gene.220  As noted above, the FDA does not 
currently regulate LDTs and, as such, the provider of a LDT may 
currently maintain its database of knowledge concerning polymorphs 
and subsequent correlation to development of disease a secret from 
regulators as well.221  The idea behind maintaining this database of 
knowledge as secret is that having a more powerful diagnostic, in 
terms of predictive capability, that can more accurately describe a 
patienW¶VSRVVLELOLW\RIGLVHDVHVKRXOGLQFUHDVHWKHFRPSHWLWLYHQHVVRI
that diagnostic in the marketplace.222  Patients and their doctors 
VKRXOGZDQWWRNQRZDVPXFKDVSRVVLEOHDERXWWKHSDWLHQW¶VVSHFLILF
                                                                                                                          
217.Trade Secret, BLACK¶S LAW DICTIONARY (9th ed. 2009) (emphasis added). 
218.Uniform Trade Secrets $FWLGHILQLQJWUDGHVHFUHWDV³LQIRUPDWLRQ
not being readily ascertainable by proper means by other persons who can obtain 
HFRQRPLFYDOXHIURPLWVGLVFORVXUHRUXVH´
219.Courtenay C. Brinckerhoff, 0\ULDG¶V7UDGH6HFUHW7UXPS&DUG7KH0\ULad 
Database of Genetic Variants, FOLEY & LARDNER, LLP, available at 
http://www.pharmapatentsblog.com/2013/07/18/the-myriad-database-of-genetic-
variants/, archived at http://perma.cc/LS6S-X2WG. 
220.Id.
221. Regulation of Genetic Tests, NATIONAL INSTITUTES OF HEALTH,
http://www.genome.gov/10002335, archived at http://perma.cc/EB7J-MWPS. 
222.See Robert Cook-Deegan et al, The Next Controversy in Genetic Testing:  
Clinical Data as Trade Secrets, EUROPEAN JOURNAL OF HUMAN GENETICS 21, 585-
588 (2013), available at 
http://www.nature.com/ejhg/journal/v21/n6/full/ejhg2012217a.html.; See also 
Brinckerhoff, supra note 219. 
32 BIOTECHNOLOGY & PHARMACEUTICAL LAW REVIEW      Vol. IX 
permutation of a disease correlated gene and that patienW¶VSHUVRQDO
risk, which would allow a diagnostic laboratory with a more        
powerful test to leverage their proprietary database into a sale to that 
particular doctor and patient.223  However, one significant problem 
with this method of maintaining competitive advantage lays in the 
fact that academic research, which is generally published and made 
widely available, will likely allow competitors to amass the same 
knowledge concerning the disease correlation of the targeted gene. 
E. Price Point Competition 
Finally, price point competition is still a viable method for       
maintaining competitiveness in the diagnostics marketplace. After 
all, patients and insurance companies are consumers of diagnostics.  
It is well established that consumers respond favorably to lower   
prices.224  A diagnostics company that is able to provide a robust and 
accurate test at a competitive price should be able to secure enough 
market share to recoup their investment.225
CONCLUSION
Many commentators on both sides predicted the grave               
consequences of the decision in Myriad.  The decision in Myriad has 
certainly shaken up the diagnostics market, but the promise of       
genetics is too great for the industry to die.  The genetic diagnostics 
industry will simply need to develop a new framework by which it 
attempts to protect investments into genetic research and diagnostics 
development.  The remaining viability of method patents should    
allow many innovator companies to focus their efforts on creating 
more accurate, efficient, and robust diagnostics with the security that 
the methods they create to do so will likely be protected by patent.  
Furthermore, federal funding into genetic research along with       
increasing private academic research due to a decrease in anxiety 
                                                                                                                          
223.Id. 
224.See Law of Demand, INVESTOPEDIA,
http://www.investopedia.com/terms/l/lawofdemand.asp, archived at 
http://perma.cc/J8RW-PVVE (explaining the economic principle known as the 
³/DZRI'HPDQG´
225.Id.
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regarding infringement suits may allow for innovator companies to 
further shift their resources toward the development of diagnostics 
and away from securing licenses to gene patents and researching the 
link between genetic polymorphs and disease.  Additionally, the 
adoption of any of several proposed regulatory exclusivity schemes 
would create a valuable, concrete, and secured incentive for genetic 
researchers and diagnostic companies to continue using the current 
exclusivity based model of protecting research and development    
investment. 
